The transcription factor Bcl11a is an oncogene in triple negative breast cancer (TNBC), the subtype with the poorest prognostic outcome. Here we perform lineage-tracing combined with single-cell RNA-sequencing (scRNAseq) to show that Bcl11a is expressed in long lived luminal progenitor cells that expand in response to MPA/DMBA mediated oncogenesis. Moreover, we find that the deletion of Bcl11a protects mice from developing tumours in the Brca1/p53 mouse model of TNBC. scRNAseq of pre-cancerous mammary epithelial cells revealed that the deletion fully reverses an aberrant differentiation behaviour of the luminal progenitor compartment associated with Brca1 loss-of-function. Finally, we show that BCL11A interacts with and recruits the chromatin remodeller CHD8, which, we demonstrate is essential for mediating the oncogenic effects of BCL11A. In summary, BCL11A promotes early stages of TNBC via its formation of context specific protein interactions making them ideal candidate for drug development.
Pensa, Sara and Lazarus, Kyren A. and Bach, Karsten and Santolla, Maria Francesca and Maggiolini, Marcello and Cassidy, John and Batra, Ankita Sati and Bruna, Alejandra and Mohammed, Hisham and Liu, Pentao and Carroll, Jason S. and Caldas, Carlos and Marioni, John C. and Khaled, Walid T., Bcl11a Marks Mammary Progenitor Cells and Promotes Early Cellular Changes Associated with TNBC by Recruiting Chd8 (2018). Available at SSRN: https://ssrn.com/abstract=3224558 or http://dx.doi.org/10.2139/ssrn.3224558
This version of the paper has not been formally peer reviewed.
Subscribe to this free journal for more curated articles on this topic
FOLLOWERS
20
PAPERS
9,156
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.